Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Genetic Technologies Limited (GENE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.1600+0.0200 (+1.75%)
At close: 03:58PM EST
1.1512 -0.01 (-0.76%)
After hours: 07:51PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetes

    MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is delighted to announce the publication of a peer-reviewed paper describing the development and validation of the polygenic risk scores that underlie the risk predictions for cardiovascular diseases and type 2 diabetes in the geneType Multi-Risk Test. The paper is coauth

  • GlobeNewswire

    Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious disease

    MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies (ASX:GTG, NASDAQ:GENE), a global leader in guideline driven Genomics based tests in health, wellness and serious disease will be hosting an interview between Dr Erika Spaeth (PhD Director of Clinical & Scientific Affairs and GTG in the US) and Adjunct Professor Charles Siles Health (Executive Director and founder of Siles Health). A/Prof. Charles Siles, Obstetrician and Gynaecologist operates nine (9) clinics across Vic

  • GlobeNewswire

    Genetype for Ovarian Cancer Published in Prestigious European Journal of Cancer Prevention

    MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is delighted to announce the publication of a validation study evaluating the performance of the geneType ovarian cancer test. This 10 year prospective cohort study utilizes data from more than 190,000 women and has been published in the prestigious European Journal of Canc

Advertisement
Advertisement